<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25397552</article-id><article-id pub-id-type="pmc">4225257</article-id><article-id pub-id-type="publisher-id">19808</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19808</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P276</subject></subj-group></article-categories><title-group><article-title>
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fabbiani</surname><given-names>Massimiliano</given-names></name><xref ref-type="aff" rid="AF0001_19808">1</xref></contrib><contrib contrib-type="author"><name><surname>Di Giambenedetto</surname><given-names>Simona</given-names></name><xref ref-type="aff" rid="AF0001_19808">1</xref></contrib><contrib contrib-type="author"><name><surname>Quiros-Roldan</surname><given-names>Eugenia</given-names></name><xref ref-type="aff" rid="AF0002_19808">2</xref></contrib><contrib contrib-type="author"><name><surname>Latini</surname><given-names>Alessandra</given-names></name><xref ref-type="aff" rid="AF0003_19808">3</xref></contrib><contrib contrib-type="author"><name><surname>Vullo</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="AF0004_19808">4</xref></contrib><contrib contrib-type="author"><name><surname>Antinori</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0005_19808">5</xref></contrib><contrib contrib-type="author"><name><surname>Castagna</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="AF0006_19808">6</xref></contrib><contrib contrib-type="author"><name><surname>Orofino</surname><given-names>Giancarlo</given-names></name><xref ref-type="aff" rid="AF0007_19808">7</xref></contrib><contrib contrib-type="author"><name><surname>Francisci</surname><given-names>Daniela</given-names></name><xref ref-type="aff" rid="AF0008_19808">8</xref></contrib><contrib contrib-type="author"><name><surname>Grilli</surname><given-names>Elisabetta</given-names></name><xref ref-type="aff" rid="AF0009_19808">9</xref></contrib><contrib contrib-type="author"><name><surname>Madeddu</surname><given-names>Giordanu</given-names></name><xref ref-type="aff" rid="AF0010_19808">10</xref></contrib><contrib contrib-type="author"><name><surname>Grima</surname><given-names>Pierfrancesco</given-names></name><xref ref-type="aff" rid="AF0011_19808">11</xref></contrib><contrib contrib-type="author"><name><surname>Rusconi</surname><given-names>Stefano</given-names></name><xref ref-type="aff" rid="AF0012_19808">12</xref></contrib><contrib contrib-type="author"><name><surname>Del Pin</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="AF0013_19808">13</xref></contrib><contrib contrib-type="author"><name><surname>Mondi</surname><given-names>Annalisa</given-names></name><xref ref-type="aff" rid="AF0001_19808">1</xref></contrib><contrib contrib-type="author"><name><surname>Borghetti</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="AF0001_19808">1</xref></contrib><contrib contrib-type="author"><name><surname>Foc&#x000e0;</surname><given-names>Emanuele</given-names></name><xref ref-type="aff" rid="AF0002_19808">2</xref></contrib><contrib contrib-type="author"><name><surname>Colafigli</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="AF0003_19808">3</xref></contrib><contrib contrib-type="author"><name><surname>De Luca</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="AF0014_19808">14</xref></contrib><contrib contrib-type="author"><name><surname>Cauda</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="AF0001_19808">1</xref></contrib></contrib-group><aff id="AF0001_19808"><label>1</label>Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy</aff><aff id="AF0002_19808"><label>2</label>University Division of Infectious and Tropical Dis, University of Brescia, Brescia, Italy</aff><aff id="AF0003_19808"><label>3</label>Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy</aff><aff id="AF0004_19808"><label>4</label>Department of Infectious Diseases, &#x0201c;La Sapienza&#x0201d; University, Rome, Italy</aff><aff id="AF0005_19808"><label>5</label>Department of Infectious Diseases, National Institute for Infectious Diseases &#x0201c;Lazzaro Spallanzani&#x0201d; IRCCS, Rome, Italy</aff><aff id="AF0006_19808"><label>6</label>Department of Infectious and Tropical Diseases, San Raffaele Scientific Institute, Milan, Italy</aff><aff id="AF0007_19808"><label>7</label>Infectious and Tropical Diseases Unit, Amedeo di Savoia Hospital, Turin, Italy</aff><aff id="AF0008_19808"><label>8</label>Infectious Diseases Clinic, University of Perugia, Perugia, Italy</aff><aff id="AF0009_19808"><label>9</label>Systemic Infections and Immunodeficiency Unit, National Institute for Infectious Diseases &#x0201c;Lazzaro Spallanzani&#x0201d; IRCCS, Rome, Italy</aff><aff id="AF0010_19808"><label>10</label>Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy</aff><aff id="AF0011_19808"><label>11</label>Division of Infectious Diseases, &#x0201c;S. Caterina Novella&#x0201d; Hospital, Galatina, Italy</aff><aff id="AF0012_19808"><label>12</label>Infectious Disease Unit, University of Milan, Milan, Italy</aff><aff id="AF0013_19808"><label>13</label>Unit of Infectious Diseases, S.M. Annunziata Hospital, Florence, Italy</aff><aff id="AF0014_19808"><label>14</label>Infectious Diseases Unit, Siena University Hospital, Siena, Italy</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19808</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Fabbiani M et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19808"><title>Introduction</title><p>We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of &#x02212;12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.</p></sec><sec id="st2_19808"><title>Methods</title><p>Subjects on ATV/r+2 NRTIs, without previous treatment failure (TF), with HIV-RNA &#x0003c;50copies/mL for &#x0003e;3 months and CD4&#x0003e;200 cells/mm<sup>3</sup> for &#x0003e;6 months were eligible. At baseline, patients were randomized to switch to ATV/r+3TC (arm one) or to maintain the original 3-drug regimen (arm two). Primary endpoint: proportion of patients free of TF at week 48. TF was defined as treatment modification for any reason, including virological failure (VF=two consecutive HIV-RNA&#x0003e;50 copies/mL or a single value &#x0003e;1000 copies/mL). Enrollment of 266 patients was planned.</p></sec><sec id="st3_19808"><title>Results</title><p>A total of 266 patients (78% males, median age 44 years, median CD4 603 cells/&#x000b5;L, 79% treated with a tenofovir-containing backbone) were enrolled. At the time of analysis, 24 weeks data were available for 84 and 87 patients in arm one and two, respectively. At baseline, subjects in the two arms did not differ for the main characteristics. At 24 weeks, at the intention to treat analysis the proportion of patients free of TF was 91.7% (95% CI 85.8&#x02013;97.6) and 85.1% (95% CI 77.6&#x02013;92.6) in arm one and two, respectively (difference +6.6%, 95% CI &#x02212;2.9/+16.1). VF was observed in two patients randomized to arm one (one at baseline, before treatment simplification) and one to arm two without resistance mutations. Clinical and laboratory adverse events occurred at similar rates in the two arms. At week 24, patients in arm one showed a greater increase in CD4 (mean change +90 vs +10 cells/&#x000b5;L, p=0.007). A greater increase in total cholesterol (+18 vs &#x02212;2 mg/dL, p&#x0003c;0.001), HDL (+4 vs +0 mg/dL, p=0.001) and LDL (+12 vs +0 mg/dL, p=0.001) was also observed in arm one without differences in other lipid parameters. Renal function showed a significant improvement in arm one (mean change in eGFR +5 vs &#x02212;2 mL/min/1.73m<sup>2</sup> in arm two, p=0.001). No significant differences in bilirubin levels or other laboratory parameters were observed between the two arms.</p></sec><sec id="st4_19808"><title>Conclusions</title><p>This interim analysis suggests a 24-weeks non-inferior efficacy of treatment simplification to ATV/rit+3TC as compared to continuation of ATV/rit +2 NRTI in virologically suppressed patients. Follow-up until 48-weeks is scheduled to confirm these data.</p></sec></abstract></article-meta></front></article>